Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N S Baber

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|June 14, 2005
Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?N S Baber
Pharmacology & Therapeutics|January 1, 1981
Clinical experience with beta adrenergic blocking agents in myocardial ischaemia: a dilemma and a challengeN S Baber
British Journal of Clinical Pharmacology|May 1, 1991
The scope of clinical pharmacology in the pharmaceutical industryN S Baber
British Journal of Clinical Pharmacology|November 9, 2000
Clinical pharmacology methodology: introductionN S Baber
British Journal of Clinical Pharmacology|June 14, 2005
Introduction to tripartite meeting report (convenors: Dr Nigel Baber and Prof. Ros Smyth): towards establishing optimal doses for drugs prescribed to childrenN S Baber, R Smyth
British Medical Journal|July 5, 1980
Beta-blockers in the treatment of myocardial infarctionN S Baber, J A Lewis
British Journal of Clinical Pharmacology|May 1, 1996
A new opportunity for training in clinical pharmacologyN S Baber, M J Brown
British Journal of Clinical Pharmacology|June 10, 2000
Clinical pharmacology and the faculty of pharmaceutical medicineP D Stonier, N S Baber
Circulation|June 1, 1983
Beta-adrenoceptor blockade and myocardial infarction: when should treatment start and for how long should it continue?N S Baber, J A Lewis
British Medical Journal (Clinical Research Ed.)|June 12, 1982
Confidence in results of beta-blocker postinfarction trialsN S Baber, J A Lewis
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|June 14, 2005
Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?N S Baber
Pharmacology & Therapeutics|January 1, 1981
Clinical experience with beta adrenergic blocking agents in myocardial ischaemia: a dilemma and a challengeN S Baber
British Journal of Clinical Pharmacology|May 1, 1991
The scope of clinical pharmacology in the pharmaceutical industryN S Baber
British Journal of Clinical Pharmacology|November 9, 2000
Clinical pharmacology methodology: introductionN S Baber
British Journal of Clinical Pharmacology|June 14, 2005
Introduction to tripartite meeting report (convenors: Dr Nigel Baber and Prof. Ros Smyth): towards establishing optimal doses for drugs prescribed to childrenN S Baber, R Smyth
British Medical Journal|July 5, 1980
Beta-blockers in the treatment of myocardial infarctionN S Baber, J A Lewis
British Journal of Clinical Pharmacology|May 1, 1996
A new opportunity for training in clinical pharmacologyN S Baber, M J Brown
British Journal of Clinical Pharmacology|June 10, 2000
Clinical pharmacology and the faculty of pharmaceutical medicineP D Stonier, N S Baber
Circulation|June 1, 1983
Beta-adrenoceptor blockade and myocardial infarction: when should treatment start and for how long should it continue?N S Baber, J A Lewis
British Medical Journal (Clinical Research Ed.)|June 12, 1982
Confidence in results of beta-blocker postinfarction trialsN S Baber, J A Lewis
Pageof 3